| Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study A Douros, S Dell’Aniello, OHY Yu, KB Filion, L Azoulay, S Suissa BMJ 362, k2693, 2018 | 135 | 2018 |
| Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study A Douros, LM Lix, M Fralick, S Dell'Aniello, BR Shah, PE Ronksley, ... Ann Intern Med 173 (6), 417-425, 2020 | 130* | 2020 |
| Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study D Abrahami, A Douros, H Yin, OHY Yu, C Renoux, A Bitton, L Azoulay BMJ 360, k872, 2018 | 122 | 2018 |
| Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study KB Filion, LM Lix, HY Oriana, S Dell’Aniello, A Douros, BR Shah, ... BMJ 370, m3342, 2020 | 101* | 2020 |
| Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events A Douros, H Yin, OHY Yu, KB Filion, L Azoulay, S Suissa Diabetes Care 40 (11), 1506-1513, 2017 | 98 | 2017 |
| Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study A Douros, M Tölle, N Ebert, J Gaedeke, D Huscher, R Kreutz, ... Eur Heart J 40 (25), 2021-2028, 2019 | 89 | 2019 |
| Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones A Douros, K Grabowski, R Stahlmann Expert Opin Drug Metab Toxicol 11 (12), 1849-1859, 2015 | 83 | 2015 |
| Drug‐induced liver injury: results from the hospital‐based Berlin Case–Control Surveillance Study A Douros, E Bronder, F Andersohn, A Klimpel, M Thomae, G Sarganas, ... Br J Clin Pharmacol 79 (6), 988-999, 2015 | 80 | 2015 |
| Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer R Kreutz, EAH Algharably, A Douros J Hypertens 37 (10), 1950-1958, 2019 | 69 | 2019 |
| Pharmacoepidemiology E Garbe, S Suissa, A Douros Handbook of epidemiology, 1-55, 2023 | 63 | 2023 |
| Safety issues and drug–drug interactions with commonly used quinolones A Douros, K Grabowski, R Stahlmann Expert Opin Drug Metab Toxicol 11 (1), 25-39, 2015 | 63 | 2015 |
| Herb-induced liver injury in the Berlin case-control surveillance study A Douros, E Bronder, F Andersohn, A Klimpel, R Kreutz, E Garbe, ... Int J Mol Sci 17 (1), 114, 2016 | 53 | 2016 |
| Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study D Abrahami, A Douros, H Yin, HY Oriana, JL Faillie, F Montastruc, ... BMJ 363, k4880, 2018 | 51 | 2018 |
| Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes A Douros, J Rouette, H Yin, OHY Yu, KB Filion, L Azoulay Diabetes Care 42 (8), 1496-1503, 2019 | 50 | 2019 |
| Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury A Douros, L Azoulay, H Yin, S Suissa, C Renoux J Am Coll Cardiol 71 (10), 1105-1113, 2018 | 49 | 2018 |
| Drug‐induced acute pancreatitis: results from the hospital‐based Berlin case–control surveillance study of 102 cases A Douros, E Bronder, F Andersohn, A Klimpel, M Thomae, J Ockenga, ... Aliment Pharmacol Ther 38 (7), 825-834, 2013 | 49 | 2013 |
| Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study KB Filion, A Douros, L Azoulay, H Yin, OH Yu, S Suissa Br J Clin Pharmacol 85 (10), 2378-2389, 2019 | 47 | 2019 |
| Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy A Douros, KB Filion, H Yin, OH Yu, M Etminan, JA Udell, L Azoulay Diabetes Care 41 (11), 2330-2338, 2018 | 45 | 2018 |
| Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review A Douros, M Ades, C Renoux CNS Drugs 32 (4), 321-334, 2018 | 36 | 2018 |
| Tocilizumab‐induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System T Flaig, A Douros, E Bronder, A Klimpel, R Kreutz, E Garbe J Clin Pharm Ther 41 (6), 718-721, 2016 | 35 | 2016 |
Laurent AzoulayMcGill universityVerified email at mcgill.ca
